State Law Protections for Employees Using Legal Cannabis Off Duty

New Jersey legalized recreational cannabis for adults through voter referendum in November 2020, and the legislature subsequently enacted CREAMMA to establish the regulatory framework for the legal cannabis market. CREAMMA includes significant employee protections that go beyond most other states' cannabis legalization laws. The statute prohibits employers from taking adverse employment actions against employees based solely on the presence of cannabis metabolites in a drug test, recognizing that cannabis metabolites can remain detectable in bodily fluids for days or weeks after use, long after any psychoactive effects have dissipated.

These protections have created considerable uncertainty for New Jersey employers, who must balance their obligations under CREAMMA with their duty to maintain safe workplaces, comply with federal contracts and regulations, and manage workplace impairment. The challenges are particularly acute in industries such as transportation, healthcare, construction, and manufacturing, where impairment can pose serious safety risks. Employers have struggled to develop drug testing and impairment assessment policies that comply with CREAMMA's requirements while preserving their ability to address legitimate safety concerns.

CREAMMA's employee protection provisions establish a multi-layered framework for workplace drug testing and impairment assessment. The statute provides that an employer may not refuse to hire or may not discharge or take any adverse action against an employee solely because of the presence of cannabinoid metabolites in the employee's bodily fluid from lawful use of cannabis outside of work. This prohibition recognizes the scientific reality that THC metabolites detected through urine testing indicate prior use but do not establish current impairment. The statutory language focuses on "lawful use" during "nonworking hours," making it clear that the protection extends only to off-duty cannabis use that complies with state law.

For assessing workplace impairment, CREAMMA establishes a reasonable suspicion standard tied to documented observations of the employee's behavior, appearance, speech, or other physical indicators. The statute requires employers to designate Workplace Impairment Recognition Experts (WIREs), individuals who have completed training in recognizing signs of cannabis impairment, to conduct impairment assessments. If a WIRE determines that an employee demonstrates observable signs of impairment, the employer may require a drug test and may take adverse action based on the combination of observed impairment and a positive test result. A positive test result alone, without observed impairment, is insufficient to support adverse action.

The opinion addresses several important exceptions to CREAMMA's protections. Employers that are required to conduct drug testing under federal law or regulation, including those subject to Department of Transportation testing requirements, are exempt from CREAMMA's limitations on adverse employment actions based on positive drug tests. Federal contractors that are required to maintain drug-free workplaces under the Drug-Free Workplace Act may also continue to enforce their existing policies. However, the opinion notes that these federal exceptions are narrower than some employers assume, and that merely holding a federal contract does not automatically exempt an employer from CREAMMA's protections.

The remedies available to employees who experience adverse employment actions in violation of CREAMMA include filing complaints with the New Jersey Cannabis Regulatory Commission (CRC) and pursuing civil actions for damages. The CRC has the authority to investigate complaints, issue findings, and order remedies including reinstatement, back pay, and compensatory damages. Employees may also pursue claims under the New Jersey Law Against Discrimination (LAD) if the adverse action is based on the employee's status as a lawful cannabis user, which may constitute disability discrimination if the employee is a registered medical cannabis patient.

CREAMMA provides significant protections for New Jersey employees who use cannabis off-duty in compliance with state law. Employers may not take adverse employment actions based solely on positive drug tests for cannabis metabolites and must instead rely on documented observations of impairment by trained Workplace Impairment Recognition Experts. Exceptions exist for federally regulated positions and safety-sensitive roles subject to federal testing requirements. Employers should review and update their drug testing policies to ensure compliance with CREAMMA, and employees should understand both their protections and the limitations on those protections.

This opinion provides essential guidance for New Jersey employers, employees, and their legal counsel. Employers should immediately review their drug testing and employment policies for CREAMMA compliance, ensure that designated WIREs have completed the required training, and update their employee handbooks to reflect the new framework. Employees who believe they have been subjected to adverse employment actions based solely on off-duty cannabis use should document the circumstances and consult with an employment attorney. Human resources professionals should develop clear protocols for impairment assessment that comply with CREAMMA's reasonable suspicion requirements. Employment defense attorneys should advise clients that the cost of CREAMMA noncompliance, including potential liability for discrimination claims, reinstatement, and back pay, can be substantial.